Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2021-07-29 Annual Report
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
10-K/A
Annual Report FY 2021
2021-07-29 English
10-K
Annual Report FY 2021
2021-06-15 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2021, reporting changes in the company's board and senior management. It details the appointment of an Interim Chief Financial Officer and the subsequent appointment of a new CFO, including biographical and compensation information. There is no financial data or report content, only management changes. This fits the category of Board/Management Information (MANG). The document length is 7648 characters, sufficient to contain substantive information about management changes rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2021-05-13 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 13, 2021, reporting the resignation of the Chief Financial Officer and President of Organovo Holdings, Inc. It details management changes including interim appointments and consulting arrangements. There is no financial data or report content, only an announcement of management changes. This fits the category of Board/Management Information (MANG). The document length is 4060 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2021-04-19 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Organovo Holdings, Inc. It registers shares reserved for issuance under an equity incentive plan. The text includes details about the securities to be registered, calculation of registration fees, incorporation by reference of other SEC filings, and indemnification provisions for directors and officers. Form S-8 is a registration statement used for securities issued under employee benefit plans and is not a financial report, earnings release, or management discussion. It is a capital market filing related to equity issuance and employee stock plans. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement, but a substantive registration statement filing.
2021-03-25 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.